Tag - MREO

Markets

Cantor starts Mereo BioPharma at OW; PT $4

Cantor Fitzgerald initiated coverage of Mereo BioPharma (NASDAQ:MREO) with an “overweight” rating and $4 price target. The stock closed at $1.15 on Aug. 11. Mereo is a clinical-stage biopharmaceutical company that is...

August 12, 2022

Markets

BTIG starts Mereo Biopharma at buy; PT $10

BTIG initiated coverage of Mereo Biopharma (NASDAQ:MREO) with a “buy” rating and price target of $10. The stock closed at $3.49 on May 4. “We believe Mereo shares are significantly undervalued with abundant proof-of...

May 5, 2021

Developments

Mereo setrusumab gets FDA rare pediatric disease designation for osteogenesis imperfecta

The FDA granted Mereo BioPharma’s (NASDAQ:MREO) setrusumab rare pediatric disease designation for the treatment of osteogenesis imperfecta (OI). OI, also known as brittle bone disease, is caused by a genetic mutation in...

September 24, 2020

Developments

Mereo BioPharma reports additional positive Phase 2b setrusumab data

Mereo BioPharma (NASDAQ:MREO) reported additional data from its Phase 2b ASTEROID clinical study of setrusumab in adults with Type 1, 3, and 4 osteogenesis imperfecta (OI). OI, also known as brittle bone disease, is...

January 14, 2020

Markets

SVB Leerink starts Mereo BioPharma at OP; PT $8

SVB Leerink initiated coverage of Mereo BioPharma Group PLC (NASDAQ:MREO) with an “outperform” rating and price target of $8. The stock closed at $2.89 on Oct. 9. “We believe this rare disease-focused biopharma company...

October 10, 2019

Developments

Mereo navicixizumab gets FDA fast track designation for ovarian cancer

Mereo BioPharma’s (NASDAQ:MREO) navicixizumab received FDA fast track designation for the treatment of high grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior...

October 8, 2019

Tag - MREO

Cantor starts Mereo BioPharma at OW; PT $4

BTIG starts Mereo Biopharma at buy; PT $10

Mereo setrusumab gets FDA rare pediatric disease designation for osteogenesis imperfecta

Mereo BioPharma reports additional positive Phase 2b setrusumab data

SVB Leerink starts Mereo BioPharma at OP; PT $8

Mereo navicixizumab gets FDA fast track designation for ovarian cancer

General

More